

Diversity, Culture and Current Treatments in Psychiatry: An Educational Forum

Course No. 24D10

The OUHSC Department of Psychiatry and Behavioral Sciences
in collaboration with the Central Oklahoma Psychiatric Society and the Tulsa Psychiatric Association.

Thursday, June 13, 2024

5:30 – 6:30 p.m. Dinner

6:30 – 8:30 p.m. CME Programs

*Abuelo's Mexican Restaurant, El Presidente Room
17 East Sheridan Avenue, Oklahoma City (Bricktown)*

“The Use of NAC (N-acetylcysteine) in the Treatment of Substance Use, NSSI, and More”

Presented by:

Rachel Zettl, MD

Clinical Assistant Professor, Child and Adolescent Psychiatry
OU College of Medicine, University of Oklahoma Health Sciences Center

Professional Practice Gaps: This presentation will review n-acetylcysteine and its pharmacologic uses in the treatment of psychiatric patients with impulse control disorders and address possible gaps in pharmacotherapeutic knowledge of an alternative treatment option that is over the counter, cost effective, and low risk compared to alternative treatments for these disorders. Improvement of patient outcomes by providing alternative treatment options for patients wanting a more “natural” approach will be reviewed.

Learning Objectives: Upon completion of this session, participants will improve their competence and performance by being able to: (1) Review what NAC is and discuss the historical uses of NAC. (2) Identify the different methods of action NAC has and how it's MOA's lead to improvements in the disease process. (3) Discover the efficacy of using NAC in various mental health disorders.

“Opioid Use Disorder Treatment in the Age of Fentanyl: Challenges and Opportunities”

Presented by:

Jedidiah Perdue, MD, MPH

Medical Director
Integrus Health Arcadia Trails Center for Addiction Recovery, Edmond

Professional Practice Gaps: Although rates of opioid use disorder have remained most stable across time, mortality rates have skyrocketed, primarily due to a change in use patterns towards fentanyl, a synthetic opioid that is highly potent and easily produced. This increased mortality heightens the need for clinicians to employ evidence-based treatments for the treatment of opioid use disorder. Both methadone and buprenorphine are associated with diminished mortality among patients with opioid use disorder, but both are underutilized. This presentation will focus on buprenorphine, an office-based option in treating OUD and principles of buprenorphine and strategies for starting this medication. The pharmacokinetics of fentanyl lead to unique challenges for the clinician utilizing buprenorphine in the treatment of opioid use disorder: the high potency and lipophilicity of fentanyl leads to greater mOPR receptor activation and a longer lead time required for induction. This presentation will explore strategies to successfully complete buprenorphine induction in a person with OUD using fentanyl, without causing precipitated withdrawal, and explore continuing treatment options to support ongoing recovery among this high-risk population.

Learning Objectives: Upon completion of this presentation, participants will improve their competence and performance by being able to: (1) Demonstrate an understanding of the unique risks posed by illicit fentanyl and the pharmacokinetic characteristics that complicate standard treatment. (2) Identify two strategies for buprenorphine induction among patients with opioid use disorder using illicit fentanyl. (3) Identify at least three harm reduction practices that have evidence in this high-risk population.

Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Oklahoma College of Medicine and the Central Oklahoma Psychiatric Society (COPS). The University of Oklahoma College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 2.00 hours of *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation Statement: The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity's speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

University of Oklahoma Equal Opportunity / Non-Discrimination Statement: The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, housing, services in educational programs or activities, or health care services that the university operates or provides.

To file a grievance related to the non-discrimination policy, report sexual misconduct, and/or file a formal complaint of sexual misconduct, please utilize the reporting form at link.ou.edu/reportingform.

Inquiries regarding non-discrimination policies may be directed to the Office(s) of Institutional Equity as may be applicable – Norman campus: (405) 325-3546/3549, Health Sciences Center: (405) 271-2110, or OU-Tulsa Title IX Office: (918) 660-3107. Additionally, individuals may visit www.ou.edu/eoo.

Accommodation Statement: For accommodations, please contact Renée Mixon, (405) 360-5066 oklapsychiatry@gmail.com.

Disclaimer Statement: Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma ("OU") nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

Policy on Planner, Presenters and Joint Provider Disclosure: It is the policy of the University of Oklahoma College of Medicine that the faculty, presenters and joint provider identify all financial relationships with ineligible companies relating to the topics of this educational activity, and also discloses discussions of off-label or investigational drugs/devices and/or therapies during their presentation(s).

Acknowledgement of Commercial and In-Kind Support: **Commercial support** is financial, or in-kind, contributions given by an ineligible company, which is used to pay all or part of the costs of a CME activity. An ineligible company is any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity received no commercial or in-kind support.

Disclosure & Mitigation Report

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its accredited CE activities. We have implemented a process where everyone who is in a position to control the content of an educational activity has identified to us all financial relationships with ineligible companies. In addition, should it be determined that a relevant financial relationship exists, this must be mitigated prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CE planners and presenters and ineligible companies for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activity's disclosure and mitigation information.

Role(s)	First Name	Last Name	Ineligible Company	Nature of the Financial Relationship
Presenter	Rachel	Zettl, MD		I have no financial relationships or affiliations with ineligible companies to disclose.
Presenter	Jedidiah	Perdue, MD		I have no financial relationships or affiliations with ineligible companies to disclose.
Course Director, Planning Committee, Moderator	Phebe M.	Tucker, MD		I have no financial relationships or affiliations with ineligible companies to disclose.
Planning Committee	Jason	Beaman, DO		I have no financial relationships or affiliations with ineligible companies to disclose.
Planning Committee	Robyn L.	Cowperthwaite, MD		I have no financial relationships or affiliations with ineligible companies to disclose.
Resident Planning Committee	Jonathan	Stone, MD		I have no financial relationships or affiliations with ineligible companies to disclose.
Planning Committee, Moderator	Irina V.	Baranskaya, MD		I have no financial relationships or affiliations with ineligible companies to disclose.
Course Contact	Renée	Mixon		I have no financial relationships or affiliations with ineligible companies to disclose.